Nachrichten

bioMérieux receives De Novo FDA Authorization for its BIOFIRE^® Joint Infection (JI) Panel

04 Mai, 2022

Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...

Alexandre Mérieux appointed Chairman and CEO of bioMérieux

15 Dezember, 2017

bioMérieux – Business review for the nine months ended September 30, 2017

18 Oktober, 2017

bioMérieux – First-Half 2017 Results

30 August, 2017

bioMérieux receives FDA 510(k) clearance for its BacT/ALERT^® VIRTUO^™ fully automated blood culture system

07 April, 2017

bioMérieux – 2016 Financial Results

01 März, 2017

bioMérieux’s VIDAS^® B•R•A•H•M•S PCT^™ becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis

24 Februar, 2017

bioMérieux and Banyan Biomarkers Partner to Develop, Validate and Market Blood-Based Biomarkers for Traumatic Brain Injury

19 Januar, 2017

bioMérieux – Fourth-Quarter 2016 Business Review

19 Januar, 2017

bioMérieux launches eMAG^®, a new generation automated system for the extraction of DNA and RNA

10 November, 2016

Business Review for the nine months ended September 30, 2016

20 Oktober, 2016

Pioneering Diagnostics